Analysis of intracellular doxorubicin and its metabolites by ultra-high-performance liquid chromatography

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 878, Issue 19, 2010, Pages 1466-1470

  Sakai Kato, Kumiko ^a   Saito, Eiko ^a   Ishikura, Keiko ^a   Kawanishi, Toru ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Doxorubicin; Doxorubicinol; Ultra high performance liquid chromatography

Indexed keywords

ANTICANCER DRUG; CARDIOTOXICITY; CELL HOMOGENATE; CONCENTRATION OF; DOXORUBICIN; DOXORUBICINOL; HIGH SENSITIVITY; HIGH-THROUGHPUT METHOD; IN-CELL; IN-VITRO; INTERNAL STANDARDS; LIMIT OF QUANTIFICATIONS; SEPARATION CONDITION; SIDE EFFECT; ULTRA-HIGH;

BIOMOLECULES; LIQUIDS; METABOLISM; METABOLITES;

LIQUID CHROMATOGRAPHY;

DAUNORUBICIN; DOXORUBICIN; DOXORUBICINOL; DOXORUBICINOLONE; DOXORUBICINON; DRUG METABOLITE; UNCLASSIFIED DRUG;

ARTICLE; CALIBRATION; CELL FREE SYSTEM; CELL LEVEL; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DETERMINATION; DRUG STRUCTURE; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOXORUBICIN; HELA CELLS; HT29 CELLS; HUMANS; INTRACELLULAR SPACE; LINEAR MODELS; SENSITIVITY AND SPECIFICITY;

EID: 77952103180     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2010.03.040     Document Type: Article

References (20)

1. Hortobagyi G.N. Drugs 54 (1997) 1
2. Di Marco A., Gaetani M., and Scarpinato B. Cancer Chemother. Rep. 53 (1969) 33
3. Olson R.D., Mushlin P.S., Brenner D.E., Fleischer S., Cusack B.J., Chang B.K., and Boucek Jr. R.J. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 3585
4. Anderson A., Warren D.J., and Slordal L. Cancer Chemother. Pharmacol. 34 (1994) 197
5. Licata S., Saponiero A., Mordente A., and Minotti G. Chem. Res. Toxicol. 13 (2000) 414
6. Sundman-Engberg B., Tidefelt U., Liliemark J., and Paul C. Cancer Chemother. Pharmacol. 25 (1990) 252
7. Zhou Q., and Chowbay B. J. Pharm. Biomed. Anal. 30 (2002) 1063
8. Aspere J.V., Tellingen O.V., and Beijnen J.H. J. Chromatogr. B: Biomed. Sci. Appl. 712 (1998) 129
9. Andersen A., Warren D.J., and Slordal L. Ther. Drug Monit. 15 (1993) 455
10. Shinozawa S., Mimaki Y., Araki Y., and Oda T. J. Chromatogr. 196 (1980) 463
11. Rose L.M., Tillery K.F., el Dareer S.M., and Hill D.L. J. Chromatogr. 425 (1988) 419
12. Andersen A., Holte H., and Slordal L. Cancer Chemother. Pharmacol. 44 (1999) 422
13. Swartz M.E. J. Liq. Chromatogr. Relat. Technol. 28 (2005) 1253
14. Novakova L., and Vlckova H. Anal. Chim. Acta 656 (2009) 8
15. Sun N., Lu G., Lin M., Fan G., and Wu Y. Talanta 78 (2009) 506
16. Maudens K.E., Stove C.P., and Lambert W.E. J. Sep. Sci. 31 (2008) 1042
17. Takanashi S., and Bachur N.R. Drug Metab. Dispos. 4 (1976) 79
18. O'Brien M.E.R., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., Catane R., Kieback D.G., Tomczak P., Ackland S.P., Orlandi F., Mellars L., and Tendler C. Ann. Oncol. 15 (2004) 440
19. Yokoyama M., Okano T., Sakurai Y., Fukushima S., Okamoto K., and Kataoka K. J. Drug Target. 7 (1999) 171
20. Nakanishi T., Fukushima S., Okamoto K., Suzuki M., Matsumura Y., Yokoyama M., Okano T., Sakurai Y., and Kataoka K. J. Control. Release 74 (2001) 295